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Description
The PI3K enzymes are a family of activation dependent lipid kinases, which have been divided into three classes (Vanhaesebroeck et al., 1999a) . PIK3CD encodes p110delta which belongs to the class I PI3Ks alongside p110alpha, p110beta and p110gamma. The PI3K enzymes are heterodimeric molecules which consist of a catalytic p110 subunit, and a constitutively bound p85 regulatory unit of which there are five isoforms encoded by three genes (PIK3R1, PIK3R2 and PIK3R3) (Vanhaesebroeck and Waterfield, 1999; Geering et al., 2007) . The regulatory subunit has a dual function of recruiting the p110 catalytic subunit to an activated upstream tyrosine kinase receptor, and inhibiting catalytic activity in the absence of this stimulatory interaction (Yu et al., 1998) .
The illustration represents the exon structure of the most prevalent transcript in leukocytes, which contains two untranslated exons upstream of the start site (-2a and -1) and 24 coding exons. p110delta protein domains. p110delta interacts with its associated p85 regulatory subunit via the adaptor binding domain (ABD). The C Lobe and N Lobe together form the catalytic domain.
Unlike p110alpha, p110delta does not phoshorylate its associated p85 regulatory subunit and instead autophosphorylates (Vanhaesebroeck et al., 1997; Vanhaesebroeck et al., 1999a) .
Expression
p110delta has a restricted expression pattern; it is highly expressed in leukocytes (Seki et al., 1997; Vanhaesebroeck et al., 1997) and to a lesser extent expressed in neurons (Eickholt et al., 2007) . In addition p110delta expression has also been observed in a number of cancerous tissues including breast cancer and melanoma cells (Sawyer et al., 2003) . A transcription factor binding cluster located immediately upstream of the untranslated exon -2a in the human gene, has been identified and found to have enhanced promotor activity in leukocytes. This promoter region may therefore facilitate the enhanced expression of p110delta in leukocytes (Kok et al., 2009) .
Localisation
p110 delta localises to the cytosol and is recruited to the periplasmic region upon stimulation of upstream activators.
Function
Cell signalling and lipid kinase activity. PI3K signalling has been found to play a crucial role in the regulation of numerous cellular processes including proliferation, metabolism (Foukas et al., 2006; Engelman et al., 2006) , and migration . Active p110delta initiates signalling cascades by phosphorylating phosphoinositide (PI) lipids such as PIP 2 producing pools of PIP 3 in the periplasmic region (Vanhaesebroeck et al., 1997) . A wide range of effector proteins recognise and interact with the PI species produced, and the resulting alteration in location and activities of these effectors initiates a number of signalling cascades. The classical effector of PI3K signalling is the serine/threonin kinase AKT (aka protein kinase B), which contains a pleckstrin homology (PH) domain that interacts with PIP 3 (Franke et al., 1997) . The affinity of Akt for PIP 3 facilitates activation of Akt's protein kinase activity, resulting in activity-modifying phosphorylation of a range of downstream Akt targets. Roles of p110delta in immune function. The role of p110delta in vivo has been studied in a p110delta null mouse (Clayton et al., 2002; Jou et al., 2002) and in a p110delta kinase-dead mouse known as p110delta D910A/D910A (Okkenhaug et al., 2002) . Phenotypic analysis of the p110delta D910A/D910A mouse revealed an important role for p110delta in immunity; the mice have notable defects in their T and B cell responses, as well as several other immunological abnormalities (Okkenhaug et al., 2002) . In vitro and ex vivo studies suggest that p110delta is the predominant PI3K class IA isoform regulating the phenotype and responses of many leukocyte cell types (Vanhaesebroeck et al., 1999b; Puri et al., 2004; Papakonstanti et al., 2008) . In mast cells derived from the p110delta kinase-dead mice, ninety percent of the total PI3K lipid kinase activity was dependent on p110delta (Ali et al., 2004) . p110delta has been found to be a key player in the induction of amongst other things, proliferation, chemotaxis, and cytokine/chemokine release in response to both physiological stimuli and pathological stimuli, in many leukocytes (Okkenhaug and Vanhaesebroeck, 2003; Dos Santos et al., 2007; Papakonstanti et al., 2008; Dil et al., 2009; Low et al., 2010) .
Homology
p110delta is most homologous to p110beta (Clayton et al., 2001 ).
Mutations
Note
No prevalent p110delta mutations have been observed in primary samples or cell lines.
Implicated in
Haematological malignancy
Note Constitutive phosphorylation of Akt (indicating constitutive activity) has been observed in many haematological malignancies, and appears to be responsible for or contributing to growth factorindependent proliferation (Min et al., 2003 , Ikeda et al., 2010 ). p110delta appears to be upstream of the constitutively active Akt in these transformed cells; p110delta-selective inhibitors significantly reduce the abberent Akt activation and also results in a reduction in proliferation (Billottet et al., 2006; Ikeda et al., 2010; Herman et al., 2010; Lannutti et al., 2011) . Despite the dominance of p110delta in the regulation of proliferation in leukocytes and the abberant activity of it's major downstream target Akt, no mutations or amplifications of p110delta have been observed in these or other haematological malignancies. A series of clinical trials are now underway to assess the effects of selective inhibition of p110delta on refractory haematological malignancies, and preliminary results are promising (Furman, 2010) . Disease CLL, T-ALL, B-ALL, DLBCL, AML, and multiple myeloma.
Allergic disease (Ali et al., 2004; Lee et al., 2006; Medina-Tato et al., 2007; Park et al., 2008 ) Note Mast cells derived from p110delta D910A/D910A mice have a degranulation defect, as do wild-type mast cells treated with a p110delta-selective inhibitor. Specifically cells lacking active p110delta showed a 45-55% reduction in degranulation induced by an antigen-IgE complex, compared to the degranulation observed in WT mast cells (Ali et al., 2004) . Furthermore inactivation of p110delta has been shown to attenuate anaphylactic responses in mice (Ali et al., 2004) . p110delta-selective inhibitors have been shown to attenuate OVA-induced influx into lungs of total leukocytes, eosinophils, neutrophils, and lymphocytes, as well as reducing the production of a number of proinflammatory mediators (Lee et al., 2006) . Disease Asthma, allergic rhinitis.
Chronic inflammatory conditions
Note p110delta has been identified as a major regulator of inflammatory responses in a wide range of leukocytes (including macrophages, neutrophils, mast cells as well as the adaptive immune cells). It it is considered an excellent potential therapeutic target for reducing inflammation both in the acute allergic context but also in the context of chronic inflammatory disorders Rommel et al., 2007) . The importance of p110delta in the regulation of inflammatory responses is highlighted by the development of spontaneous chronic colonic inflammation in the p110delta D910A/D910A mice, which has been attributed to a failure to repress inflammatory responses to commensal bacteria in the gut (Uno et al., 2010) . Thus p110delta-selective drugs are currently under investigation as a treatment for rheumatoid arthritis, asthma and other inflammatory conditions. Disease Rheumatoid arthritis, inflammatory bowel disease (IBD).
